



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

### Lupin launches Generic Trilipix® Delayed-Release Capsules 45 mg & 135 mg in the US

**Mumbai, Baltimore, December 06, 2013:** Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Fenofibric Acid Delayed-Release Capsules 45 mg and 135 mg. Lupin had earlier received final approval from the US FDA for the same.

Lupin's Fenofibric Acid Delayed-Release Capsules 45 mg and 135 mg are the generic equivalent of AbbVie Inc.'s Trilipix® Delayed-Release Capsules 45 mg & 135 mg strengths are indicated as co-administration therapy with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.

Trilipix® Delayed-Release Capsules 45 mg & 135 mg strengths had annual U.S sales of approximately US\$ 449.5 million (IMS MAT Sep, 2013).

#### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by revenues. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit <http://www.lupinworld.com> for more information.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>

#### **For more information, please contact -**

Shamsher Gorawara  
Head – Corporate Communications  
Ph: +91 98 20 338 555  
Email: [shamshergorawara@lupinworld.com](mailto:shamshergorawara@lupinworld.com)  
or

Alpesh Dalal  
Head – M & A and Investor Relations  
Lupin Limited  
Ph: +91 98 20 023 511  
Email: [alpeshdalal@lupinpharma.com](mailto:alpeshdalal@lupinpharma.com)

#### **Safe Harbor Statement**

\* Trilipix® is a registered trademark of AbbVie Inc.